Loading
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.
Regular session
$0.9559
−$0.0215 · -2.20%
Regular session · ET · Market data may be delayed.
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.
Day range
Current $0.9559
52-week range
Current $0.9559
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
37
Expensive
Sentiment
49
Mixed
Risk
74
High Risk
Momentum
38
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.
Day range
Current $0.9559
52-week range
Current $0.9559
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 4.41M USD | 4.06M USD | 6.04M USD | 2.49M USD | — |
| Cost of goods sold | 2.39M USD | 1.97M USD | 704K USD | — | — |
| Gross profit | 2.02M USD | 2.09M USD | 5.33M USD | 2.49M USD | — |
| Research and development | 39.75M USD | 32.13M USD | 39.57M USD | 56.16M USD | 35.11M USD |
| Selling, general, and administrative | 27.58M USD | 26.69M USD | 31.99M USD | 35.4M USD | 22.92M USD |
| Operating expenses | 64.94M USD | 56.84M USD | 70.86M USD | 91.56M USD | 58.03M USD |
| Interest income | 922K USD | 1.3M USD | 2.5M USD | 1.4M USD | — |
| Interest expense | 5.19M USD | — | — | — | 79K USD |
| Depreciation and amortization | 2.39M USD | 1.97M USD | 704K USD | 480K USD | 229K USD |
| Operating income | −62.92M USD | −54.76M USD | −65.53M USD | −89.07M USD | −58.03M USD |
| Net income | −67.85M USD | −54.05M USD | −63.08M USD | −86.8M USD | −58.37M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$5.00
423.07% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Sep 30, 2019 | 1:60 | — | — |
Effective Sep 30, 2019
1:60
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI13.54M0.00%2.3T USD0.03%$381.21+0.43%
State Street SPDR S&P Biotech ETFXBI11.13M0.11%10.11B USD0.35%$153.31+2.69%
iShares Russell 2000 ETFIWM8.9M0.01%77.7B USD0.19%$278.56+0.36%
Vanguard Extended Market ETFVXF5.23M0.01%95.4B USD0.05%$234.41+0.55%
Vanguard Russell 2000 ETFVTWO2.61M0.01%18B USD0.06%$112.52+0.37%
iShares Russell 2000 Growth ETFIWO2.15M0.02%14.04B USD0.24%$355.85+0.67%
State Street SPDR S&P Kensho New Economies Composite ETFKOMP1.85M0.07%2.64B USD0.20%$66.165+0.85%
Vanguard Health Care ETFVHT1.33M0.01%22B USD0.09%$317.73+1.24%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOState Street SPDR S&P Kensho New Economies Composite ETFKOMPVanguard Health Care ETFVHTAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
